Please assess the completion status of the following clinical trial:

Trial Title: Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 14.0

Eligibility Criteria:
Inclusion Criteria:~All subjects must satisfy ALL the following criteria at study entry:~* Subjects who the investigator believes that parent(s)/Legally Acceptable Representative(s) \[LAR(s)\] can and will comply with the requirements of the protocol~* Children, male or female between, and including, 6 and 35 months of age at the time of the first vaccination.~* Written informed consent obtained from the parent(s)/LAR(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Age appropriate scheduled childhood vaccinations completed to the best of parent(s)/LAR(s) knowledge.~* Born after gestation period of 36 to 42 weeks inclusive~Exclusion Criteria:~The following criteria should be checked at the time of study entry. If ANY exclusion criterion applies, the subject must not be included in the study:~* Child in care~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Prior receipt of any influenza vaccination or planned administration during the study period.~* Planned administration of any vaccine 30 days prior and 30 days after any study vaccine administration.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* A family history of congenital or hereditary immunodeficiency.~* A family history of febrile seizures or/and epilepsy~* Any known or suspected allergy to any constituent of influenza or routine paediatric vaccines, a history of severe adverse reaction to any previous vaccination; or a history of anaphylactic-type reaction to any constituent of influenza vaccine.~* History of any progressive neurological disorders or seizures.~* Acute or chronic, clinically-significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by medical history or physical examination.~* Acute disease and/or fever at the time of enrolment:~* - Fever is defined as temperature ≥ 37.5°C on oral, axillary or tympanic setting, or ≥38.0°C on rectal setting.~* Subjects with a minor illness without fever might be enrolled at the discretion of the investigator.~* Administration of immunoglobulins and/or any blood products within the 3 month preceding the first dose of study vaccine or planned administration during the study period.~* Any condition which, in the opinion of the investigator, render the subject unfit for participation in the study.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 35 Months
- Healthy Volunteers: t

Study Arms:
- GSK2584786A vaccine 1 dose of Formulation A1 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
- GSK2584786A vaccine 2 doses of Formulation A1 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A1.
- GSK2584786A vaccine 1 dose of Formulation A2 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
- GSK2584786A vaccine 2 doses of Formulation A2 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A2.
- GSK2584786A vaccine 1 dose of Formulation A3 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
- GSK2584786A vaccine 2 doses of Formulation A3 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation A3.
- GSK2584786A vaccine 1 dose of Formulation B1 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
- GSK2584786A vaccine 2 doses of Formulation B1 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B1.
- GSK2584786A vaccine 1 dose of Formulation B2 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
- GSK2584786A vaccine 2 doses of Formulation B2 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B2.
- GSK2584786A vaccine 1 dose of Formulation B3 Group (Type: EXPERIMENTAL): Subjects received 1 dose of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
- GSK2584786A vaccine 2 doses of Formulation B3 Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' adjuvanted quadrivalent influenza candidate vaccine (GSK2584786A) Formulation B3.
- GSK2321138A vaccine Group (Type: EXPERIMENTAL): Subjects received 2 doses of GSK Biologicals' non-adjuvanted quadrivalent influenza candidate vaccine (GSK2321138A).
- Fluarix Group (Type: ACTIVE_COMPARATOR): Subjects received 2 doses of Fluarix Vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).